{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihqgj3zpxl4sd7n7mfch4dxmnalj6looyo4gxsev5cmqvsruq2n3m",
    "uri": "at://did:plc:6pwit4ctv4egvys3qyqmgbi6/app.bsky.feed.post/3mlowe32yz4e2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigowl2zlledwedxthmeubwbxjyqczifkhnpb6cohtsrvd2pry7kyi"
    },
    "mimeType": "image/jpeg",
    "size": 63197
  },
  "path": "/health/new-option-available-alzheimers-patients-fda-approves-expanded-drug-use",
  "publishedAt": "2026-05-12T22:00:20.000Z",
  "site": "https://www.foxnews.com",
  "tags": [
    "1d48c920-4df5-548e-a84a-0048423f809a",
    "fnc",
    "Fox News",
    "fox-news/health",
    "fox-news/health/nervous-system-health/alzheimers",
    "fox-news/health/geriatric-health",
    "fox-news/health/mental-health/depression",
    "fox-news/health/healthy-living/medications",
    "fox-news/health/mental-health/bipolar-disorder",
    "fox-news/lifestyle",
    "fox-news/health/mental-health",
    "article"
  ],
  "textContent": "The FDA has approved Auvelity as the first non-antipsychotic treatment for agitation in Alzheimer's disease, marking a major milestone for patients.",
  "title": "New option available for Alzheimer’s patients as FDA approves expanded drug use"
}